Moderna Receives Refusal-to-File Letter from the U.S. Food and Drug Administration for Its Investigational Seasonal Influenza Vaccine, mRNA-1010

Refusal to review the submission is inconsistent with feedback at pre-Phase 3 and pre-submission consultations; Moderna has ...

Moderna Announces Strategic Collaboration with Recordati to Globally Commercialize Investigational Propionic Acidemia Therapeutic (mRNA-3927)

Moderna will continue to lead clinical development and manufacturing for mRNA-3927Moderna to receive up to $160 million ...
San Diego Union-Tribune

Opinion: mRNA medicines are the future of modern health — not a threat

Since the announcements by federal health authorities earlier this year that federal mRNA vaccine funding will be curtailed, a fierce debate has taken place around the future of mRNA-based ...
HUB

The disease-fighting promise of mRNA

In recent years, mRNA technology enabled the rapid development of vaccines to fight COVID-19, saving millions of lives. That same mRNA-powered approach to medicine—in which synthetic mRNA is ...

Moderna CEO hails breakthrough mRNA cancer vaccine that halves melanoma recurrence risk with Keytruda

Breakthrough personalized mRNA vaccine cuts melanoma recurrence risk by 50% when combined with Keytruda, Moderna CEO reveals ...

The New Standard of mRNA R&D: Creative Biolabs Combines Methylation Assays with saRNA Synthesis

Leveraging its integrated "design-synthesis-quality control" system, Creative Biolabs is overcoming bottlenecks in mRNA ...
Seeking Alpha

MaxCyte Joins the Alliance for mRNA Medicines (AMM) as a Founding Member

ROCKVILLE, Md., Nov. 16, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (MXCT), (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling ...

No association between mRNA COVID-19 vaccination during pregnancy and autism in children, new research shows

The mRNA COVID-19 vaccine is not associated with autism or other neurodevelopmental problems in children whose mothers ...